We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Roche Holding AG (RO) CHF1(Bearer)

Sell:273.00 CHF Buy:273.20 CHF Change: 3.60 CHF (1.34%)
Market closed |  Prices as at close on 25 November 2024 | Switch to live prices |
Sell:273.00 CHF
Buy:273.20 CHF
Change: 3.60 CHF (1.34%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 25 November 2024 | Switch to live prices |
Sell:273.00 CHF
Buy:273.20 CHF
Change: 3.60 CHF (1.34%)
Market closed |  Prices as at close on 25 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Contact details

Address:
Grenzacherstrasse 124
BASEL
4002
Switzerland
Telephone:
+41 (9) 732354295
Website:
https://www.roche.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RO
ISIN:
CH0012032113
Market cap:
207.43 billion CHF
Shares in issue:
796.79 million
Sector:
Pharmaceuticals
Exchange:
SIX Swiss Exchange
Country:
Switzerland
Currency:
Swiss Franc
Indices:
Swiss All Share Index

Key personnel

  • Thomas Schinecker
    Chief Executive Officer, Member of the Corporate Executive Committee
  • Alan Hippe
    Member of the Corporate Executive Committee, Chief Financial and Information Officer
  • Cristina Wilbur
    Member of the Corporate Executive Committee, Chief People Officer
  • Pascale Schmidt
    Chief Compliance Officer
  • Claudia Boeckstiegel
    Member of the Enlarged Corporate Executive Committee, General Counsel
  • Silke Hoernstein
    Member of the Enlarged Corporate Executive Committee, Head Corporate Strategy and Sustainability, Secretary to the Corporate Executive Committee
  • Hans Clevers
    Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research and Early Development (pRED)
  • Levi Garraway
    Member of the Enlarged Corporate Committee, Head of Global Product Development and Chief Medical Officer
  • Teresa Graham
    Member of the Corporate Executive Committee, Chief Executive Officer of Roche Pharmaceuticals
  • Aviv Regev
    Member of the Enlarged Corporate Executive Committee, Head Genentech Research and Early Development (gRED)

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.